New compound V-161 offers hope in the fight against antibiotic-resistant bacteria

V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization.

Single-cell study reveals clues to epigenetic drug response in Myelodysplastic Syndrome

Researchers from the Josep Carreras Leukaemia Research Institute, spearheaded by the Cancer Epigenetics group led by Dr. Manel Esteller, described the effects of chemotherapy at

February 6, 2024

Eli Lilly has tapped telehealth startup Ro to distribute its single-dose Zepbound vials

Through a new relationship with Eli Lilly, Ro patients can now get easier access to the drugmaker’s discounted, single-dose vials of blockbuster obesity drug Zepbound

December 12, 2024

Quantum simulation drives breakthrough in drug development

Led by University of Melbourne theoretician and HPC expert Associate Professor Giuseppe Barca, a research team has achieved the first quantum simulation of biological systems

July 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.